Minimum Power and Frequency of Repeated Low-level Red-light to Effectively Control Myopia Progression

Recruiting now · Not applicable

Conditions studied: Myopia, Refractive Error - Myopia, Choroidal Thickness, Retina

In brief

To explore the minimum power and frequency of Repeated Low-level Red-light (RLRL) to control myopia progression in low-myopic children aged 8-10 years, and the rebound effect of low-myopic children after discontinuation of RLRL with different combinations of power and frequency.

Key facts

Study ID: NCT06717048
Run by: Shanghai Eye Disease Prevention and Treatment Center
People needed: 108
Starts: 2024-12-09
Expected to finish: 2025-06-09
Last updated by the study team: 2024-12-04

Who can join

Age: 8 and older, up to 10. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Age: 8-10 years old
Low myopia: cycloplegic spherical equivalent refractions (SERs) range from -0.50 (inclusive) to -3.00 diopters (D) and astigmatism less than -2.5 D in either eye.
signed informed consent and was able to participate in the study

You may not qualify if…

Secondary myopia, such as a history of retinopathy of prematurity or other neonatal diseases; syndromic myopia with a known genetic disorder or connective tissue disease, such as Stickler syndrome or Marfan syndrome
Strabismus or other binocular vision abnormalities
Cloudy refractive media: cloudy cornea, cataract or intraocular lens surgery
Eye diseases that affect retinal function: macular degeneration, diabetic retinopathy, retinal detachment, glaucoma or ocular hypertension, endophthalmitis, uveitis, optic neuropathy, etc.
History of refractive surgery, internal eye surgery, laser therapy, vitreous injection, etc.
diabetes, hypertension and other systemic disorders
History of use of retinal toxic drugs, such as hydroxychloroquine, etc.
Use of orthokeratology, atropine, multifocal frame glasses and other myopia control methods; children who are currently receiving atropine, orthokeratology, multifocal frame glasses and other myopia control treatment, can be enrolled after 2 weeks of treatment.
Other reasons considered unsuitable for inclusion by the study physician, including but not limited to other ocular and systemic disease abnormalities

Where it is running

Shanghai Eye Disease Prevention & Treatment Center — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.